Propanc Biopharma Inc (OTCMKTS:PPCBD), a biopharmaceutical company focused on using pancreatic proenzymes to treat recurring and metastatic cancer, said it has published key data regarding its lead drug PRP in the medical journal Scientific Reports.
In a statement, the company said it’s researchers, in collaboration with the Universities of Jaén and Granada in Spain, conducted a study that confirmed the effects of PRP against cancer stem cells, a select group of cells within tumors that are capable of self-renewal and often resist chemotherapy.
PRP is a formulation of two pancreatic proenzymes, which work together to fight malignant tumors. The results of the study come as Propanc is preparing for a First-in-Human trial of the drug in 2020.
READ: Propanc Biopharma moves closer to first-in-human study by quantifying ingredients for its metastatic cancer drug
“We are excited to publish this paper on our work with PRP and CSCs, where these cells drive cancer,” Propanc's Chief Science Officer Julian Kenyon said in the statement.
“PRP has multiple modes of action, quite unlike any other cancer drug and is clearly in a class of its own. This is likely to translate into PRP being effective in many different cancer types and reducing the recurrence rate after standard treatments.”
The Scientific Reports article is entitled “Pancreatic proenzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumor engrafting”
Propanc's share price slid 9.6% to $1.99 on Monday.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel